Kresten Skak

1.5k total citations
37 papers, 1.2k citations indexed

About

Kresten Skak is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Kresten Skak has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 12 papers in Oncology and 10 papers in Genetics. Recurrent topics in Kresten Skak's work include Immune Cell Function and Interaction (17 papers), Immunotherapy and Immune Responses (10 papers) and Diabetes and associated disorders (8 papers). Kresten Skak is often cited by papers focused on Immune Cell Function and Interaction (17 papers), Immunotherapy and Immune Responses (10 papers) and Diabetes and associated disorders (8 papers). Kresten Skak collaborates with scholars based in Denmark, United States and Australia. Kresten Skak's co-authors include Klaus Stensgaard Frederiksen, Dorthe Lundsgaard, Ian D. Davis, Henrik Søndergaard, Mark J. Smyth, Pallavur V. Sivakumar, Birte K. Skrumsager, Grant A. McArthur, B Michelsen and Paul E.G. Kristjansen and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Kresten Skak

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kresten Skak Denmark 18 839 517 192 143 135 37 1.2k
Frann Bennett United States 10 1.1k 1.4× 407 0.8× 162 0.8× 95 0.7× 153 1.1× 14 1.5k
Dorthe Lundsgaard Denmark 12 824 1.0× 335 0.6× 96 0.5× 123 0.9× 158 1.2× 23 1.0k
Fumi Miyagawa Japan 15 587 0.7× 294 0.6× 240 1.3× 44 0.3× 119 0.9× 52 1.2k
Paul Hobby United Kingdom 16 954 1.1× 344 0.7× 218 1.1× 61 0.4× 56 0.4× 24 1.3k
Satoshi Kojo Japan 23 1.5k 1.8× 409 0.8× 335 1.7× 119 0.8× 36 0.3× 38 2.0k
Ryuta Mukasa Japan 7 912 1.1× 184 0.4× 221 1.2× 83 0.6× 35 0.3× 11 1.1k
John L. Langowski United States 9 849 1.0× 628 1.2× 279 1.5× 78 0.5× 91 0.7× 20 1.3k
Sothy Yi United States 5 719 0.9× 214 0.4× 217 1.1× 52 0.4× 163 1.2× 10 997
Jérôme Giustiniani France 21 922 1.1× 456 0.9× 259 1.3× 40 0.3× 82 0.6× 45 1.4k
Deborah D. Glass United States 18 1.3k 1.6× 329 0.6× 172 0.9× 130 0.9× 21 0.2× 22 1.6k

Countries citing papers authored by Kresten Skak

Since Specialization
Citations

This map shows the geographic impact of Kresten Skak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kresten Skak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kresten Skak more than expected).

Fields of papers citing papers by Kresten Skak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kresten Skak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kresten Skak. The network helps show where Kresten Skak may publish in the future.

Co-authorship network of co-authors of Kresten Skak

This figure shows the co-authorship network connecting the top 25 collaborators of Kresten Skak. A scholar is included among the top collaborators of Kresten Skak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kresten Skak. Kresten Skak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ulrich, Martina, Susanne Lange‐Asschenfeldt, Kresten Skak, et al.. (2016). Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.. PubMed. 15(10). 1181–1189. 10 indexed citations
3.
4.
Le, Thuy T., Kresten Skak, Kate Schroder, et al.. (2016). IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate. PLoS ONE. 11(4). e0153975–e0153975. 17 indexed citations
5.
Erlendsson, Andrés M., Daniel Thaysen‐Petersen, Christiane Bay, et al.. (2016). Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice. PLoS ONE. 11(9). e0162597–e0162597. 6 indexed citations
6.
Freiberger, Sandra N., Phil F. Cheng, Piotr Dziunycz, et al.. (2015). Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 14(9). 2132–2142. 35 indexed citations
7.
Davis, Ian D., Richard Kefford, Michael Millward, et al.. (2009). Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research. 15(6). 2123–2129. 120 indexed citations
8.
Søndergaard, Henrik, Jonathan M. Coquet, Adam P. Uldrich, et al.. (2009). Endogenous IL-21 Restricts CD8+ T Cell Expansion and Is not Required for Tumor Immunity. The Journal of Immunology. 183(11). 7326–7336. 15 indexed citations
9.
Søndergaard, Henrik & Kresten Skak. (2009). IL‐21: roles in immunopathology and cancer therapy. Tissue Antigens. 74(6). 467–479. 52 indexed citations
10.
Skak, Kresten, Henrik Søndergaard, Klaus Stensgaard Frederiksen, & E. Ehrnrooth. (2009). In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics. Cytokine. 48(3). 231–238. 4 indexed citations
11.
Frederiksen, Klaus Stensgaard, Dorthe Lundsgaard, Jeremy A. Freeman, et al.. (2008). IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology Immunotherapy. 57(10). 1439–1449. 85 indexed citations
12.
Dodds, Michael, Klaus Stensgaard Frederiksen, Kresten Skak, et al.. (2008). Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunology Immunotherapy. 58(6). 843–854. 21 indexed citations
13.
Eriksen, Karsten W., Henrik Søndergaard, Anders Woetmann, et al.. (2008). The combination of IL-21 and IFN-α boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Molecular Immunology. 46(5). 812–820. 18 indexed citations
14.
Davis, Ian D., Birte K. Skrumsager, Jonathan Cebon, et al.. (2007). An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. Clinical Cancer Research. 13(12). 3630–3636. 132 indexed citations
15.
Barker, Brianne R., et al.. (2007). IL-21 Induces Apoptosis of Antigen-Specific CD8+ T Lymphocytes. The Journal of Immunology. 179(6). 3596–3603. 30 indexed citations
16.
Skak, Kresten, Klaus Stensgaard Frederiksen, & Dorthe Lundsgaard. (2007). Interleukin‐21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 123(4). 575–583. 120 indexed citations
17.
Søndergaard, Henrik, Klaus Stensgaard Frederiksen, Peter Thygesen, et al.. (2007). Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunology Immunotherapy. 56(9). 1417–1428. 59 indexed citations
18.
Skak, Kresten, et al.. (2003). TNF‐α impairs peripheral tolerance towards β‐cells, and local costimulation by B7.1 enhances the effector function of diabetogenic T cells. European Journal of Immunology. 33(5). 1341–1350. 13 indexed citations
19.
Pedersen, Anette A., et al.. (2002). PDX-1 mediates glucose responsiveness of GAD67, but not GAD65, gene transcription in islets of Langerhans. Biochemical and Biophysical Research Communications. 295(2). 243–248. 8 indexed citations
20.
Skak, Kresten & B Michelsen. (1999). The TATA-less rat GAD65 promoter can be activated by Sp1 through non-consensus elements. Gene. 236(2). 231–241. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frann Bennett Breakdown of academic impact, for papers by Dorthe Lundsgaard Breakdown of academic impact, for papers by Fumi Miyagawa Breakdown of academic impact, for papers by Paul Hobby Breakdown of academic impact, for papers by Satoshi Kojo Breakdown of academic impact, for papers by Ryuta Mukasa Breakdown of academic impact, for papers by John L. Langowski Breakdown of academic impact, for papers by Sothy Yi Breakdown of academic impact, for papers by Jérôme Giustiniani Breakdown of academic impact, for papers by Deborah D. Glass
Rankless by CCL
2026